Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability and LDL-C lowering with AMG 145 versus ezetimibe in statin-intolerant hypercholesterolemia
2011-001529-26Phase 2Completed
- Sponsor
- Amgen
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of evolocumab in hypercholesterolemia (3 arms), sponsored by Amgen. Primary endpoint: Percent change from baseline in LDL-C at week 12. Started May 2011; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2011-001529-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001529-26.